Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis
Martin Briand, MS*,1,
Isabelle Lemieux, PhD*,
Jean G. Dumesnil, MD, FACC*,
Patrick Mathieu, MD*,
Amélie Cartier, MS*,
Jean-Pierre Després, PhD, FAHA*, ,3,
Marie Arsenault, MD*,4,
Jacques Couet, PhD*,4 and
Philippe Pibarot, DVM, PhD, FACC*,2,*
* Laval Hospital Research Center/Québec Heart Institute, Department of Medicine, Laval University, Québec, Canada
Division of Kinesiology, Department of Social and Preventive Medicine, Laval University, Québec, Canada
View larger version (59K):
[in a new window]
|
Figure 1 Rate of progression of aortic valve area (AVA) with presence (orange bars) or absence (blue bars) of age  70 years, male gender, hypertension (HPT), obesity, history of hypercholesterolemia (Hyperchol), history of smoking, diabetes, and metabolic syndrome (MS).
|
|
View larger version (30K):
[in a new window]
|
Figure 2 Rate of progression of aortic valve area (AVA) among the two groups separated according to the median value of the Framingham score in patients with metabolic syndrome (MS) (orange bars) and those without MS (blue bars). Significant difference versus group 2 (p < 0.05).
|
|
View larger version (30K):
[in a new window]
|
Figure 3 Rate of progression of aortic valve area (AVA) among the two groups separated according to the presence or absence of statin therapy in patients with metabolic syndrome (MS) (orange bars) and those without MS (blue bars). *Significant difference versus group 1 (p < 0.05); significant difference versus group 2 (p < 0.05).
|
|
View larger version (15K):
[in a new window]
|
Figure 4 Kaplan-Meier analysis of event-free survival in 40 patients with metabolic syndrome (MS) compared with 65 patients without MS.
|
|
|
